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Background: MicroRNAs (miRNAs) have been proved to play important roles in the tumorigenesis and
development of human gastric cancer (GC). Our study aims to investigate the expression and clinical significance of
miR-198 in GC patients.
Methods: Quantitative real-time polymerase chain reaction (RT-PCR) was performed to evaluate miR-198 levels in
106 pairs of GC specimens and adjacent noncancerous tissues. Then, the associations of miR-198 expression with
clinicopathological factors and patient’s survival were determined.
Results: The expression levels of miR-198 in GC tissues were significantly lower than those in corresponding
noncancerous tissues (p < 0.01). Decreased miR-198 expression was significantly associated with larger tumor size,
deeper invasion depth, positive lymph node metastasis, advanced tumor-node-metastasis (TNM) stage, and shorter
overall survival. Moreover, multivariate regression analysis identified low miR-198 expression as an independent
predictor of poor survival.
Conclusions: These findings suggested that miR-198 downregulation may be associated with progression of GC
and that this miR may be an independent prognostic marker for GC patients.
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Gastric cancer (GC) is the fourth most prevalent human
malignancy and the second leading cause of cancer
death worldwide [1]. The majority of GC patients are di-
agnosed at advanced stage due to vague initial symptoms
[2]. Despite recent advances in surgical techniques, new
chemotherapy regimens, radiotherapy, and molecular
targeted therapy, the clinical outcome of patients with
GC remains dismal, with a 5-year survival rate of 25 %
or less [3]. Previous studies have reported many onco-
genes and tumor suppressor genes closely associated
with GC [4–6], but the highly complex molecular mech-
anisms underlying its carcinogenesis and progression are
still obscure. Therefore, it is urgent to identify reliable
biomarkers of GC for its early diagnosis, effective ther-
apy, and prognosis evaluation.* Correspondence: dockongdi@163.com
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ring, short (about 22 nucleotides in length), single-
stranded, non-protein-coding RNAs that negatively
regulate gene expression [7]. It is estimated that about
60 % genes can be regulated by miRNAs [8]. They sup-
press translation or promote the degradation of target
messenger RNAs (mRNAs) through base pairing with
the 3 -untranslated regions (3 -UTRs) [7, 9]. Previous
research has shown that miRNAs have critical roles in
various biological processes, such as development, differ-
entiation, cell growth, inflammation, stress response, and
endocrine homeostasis [10]. Emerging evidence demon-
strates that aberrant miR expression is highly associated
with cancer initiation and progression, which may
provide a new but promising way to deal with cancer
[11–13]. miRNAs can function as either oncogenes or
tumor suppressors according to the roles of their tar-
get genes. Deregulation or dysfunction of miRNAs is
involved in many processes of tumor progressionistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Table 1 Correlation between miR-198 expression and different







≥60 36 (48.0 %) 39 (52.0 %)
<60 17 (54.8 %) 14 (45.2 %) 0.336
Gender
Male 28 (46.7 %) 32 (53.3 %)
Female 25 (54.3 %) 21 (45.7 %) 0.278
Differentiation
Well-moderate 14 (41.2 %) 20 (58.8 %)
Poor 39 (54.2 %) 33 (45.8 %) 0.149
Lauren type
Intestinal 29 (43.9 %) 37 (56.1 %)
Diffuse and mixed 24 (60.0 %) 16 (40.0 %) 0.08
Tumor size
≥5 cm 38 (60.3 %) 25 (39.7 %)
<5 cm 15 (34.9 %) 28 (65.1 %) 0.009
Invasion depth
T1, T2 16 (34.8 %) 30 (65.2 %)
T3, T4 37 (61.7 %) 23 (38.3 %) 0.005
TNM stage
I/II 13 (35.1 %) 24 (64.9 %) 0.02
III 40 (58.0 %) 29 (42.0 %)
Lymphatic metastasis
Negative 12 (35.3 %) 22 (64.7 %) 0.03
Positive 41 (56.9 %) 31 (43.1 %)
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angiogenesis, and epithelial-to-mesenchymal transition
[14–16]. Functional miRNAs may be applied for cancer
diagnosis and prognosis and also act as potential novel
therapeutic targets.
miR-198 is a recently identified cancer-related miR. It
is observed to be downregulated in lung cancer [17],
colorectal cancer [18], hepatocellular carcinoma [19],
pancreatic cancer [20], ovarian cancer [21], and prostate
cancer [22], and acts as a potential tumor suppressor in
these tumors. Yet miR-198 was reported to be upregu-
lated in retinoblastoma and squamous cell carcinoma of
the tongue [23, 24], indicating that miR-198 may not be-
have as a tumor suppressor in all cases. However, the ex-
pression and clinical significance of miR-198 in GC is
still unclear. In the present study, we examined miR-198
expression in GC tissues and paired adjacent noncancer-
ous tissues. The relationship between miR-198 expression
and clinicopathological features and patient’s survival was
also analyzed.
Methods
Patients and clinical specimens
This study was approved by the Research Ethics Committee
of Tianjin Nankai Hospital. Written informed consent
was obtained from all of the patients. All specimens
were handled and made anonymous according to the
ethical and legal standards.
Fresh primary GC tissues and matched normal adjacent
tissues (≥3 cm away from tumor margin) were obtained
from 106 consecutive patients who received radical exci-
sion at Tianjin Nankai Hospital between February 2007
and June 2010. The diagnosis of all samples was histo-
pathologically confirmed by two pathologists. All speci-
mens were frozen immediately in liquid nitrogen and
stored at −80 °C until analysis. Patients with two or more
different malignancies were excluded. None of the patients
had received preoperative radiotherapy or chemotherapy.
Patient characteristics are shown in Table 1. Tumors were
staged according to the tumor-node-metastasis (TNM)
staging system of the International Union Against Cancer.
Follow-up data were available for all patients. Overall sur-
vival was defined as the amount of time from the day of
primary surgery to the date of death or the end of follow-
up (for living patients).
RNA extraction and quantitative real-time polymerase
chain reaction (PCR)
Total RNA was extracted from clinical specimens by
using Trizol reagent (Invitrogen Corp, Carlsbad, CA,
USA) according to the manufacturer’s instructions. RNA
concentration was measured using a NanoDrop ND-1000
spectrophotometer (Thermo Scientific, Wilmington, DE).
Complementary DNA (cDNA) was synthesized fromisolated RNA using TaqMan MicroRNA Reverse
Transcription Kit and miRNA-specific stem-loop
primers (both from Applied Biosystems, Foster City,
CA, USA). Real-time PCR was performed with a
Taqman MicroRNA Assay Kit (Applied Biosystems)
on ABI7500 real-time PCR detection system. Quantitative
PCR was conducted at 95 °C for 10 min followed by 40 cy-
cles of 95 °C for 15 s and 60 °C for 60 s. U6 small nuclear
RNA was used as an internal control. All reactions were
run in triplicates. The cycle threshold (CT) values
were recorded, and the relative amount of miR-198 to
U6 was calculated using the equation 2−ΔCT, where
ΔCT = (CTmiR-198 − CTU6).
Statistics
All statistical analyses were performed using the SPSS
16.0 software package (SPSS, Chicago, IL, USA). The
significance of differences between groups was estimated
by Student’s t test and Chi-square test. Survival curves
were constructed with the Kaplan-Meier method and
compared by log-rank test. The significance of survival
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tional hazards regression analysis. p < 0.05 was consid-
ered statistically significant.
Results
Downregulation of miR-198 in human GC tissues
miR-198 expression was detected in 106 pairs of GC and
corresponding adjacent noncancerous tissues normalized
to U6 small nuclear RNA. As shown in Fig. 1, miR-198
expression in cancer tissues was distinctly decreased
compared to noncancerous tissues. The results showed
that the relative level of miR-198 expression in GC
samples (mean ± SD 7.05 ± 1.98) was significantly lower
than that in corresponding adjacent normal tissues
(mean ± SD 18.38 ± 4.30; p < 0.01).
Correlation between miR-198 expression and clinical
features of GC
We further analyzed the association between miR-198
expression levels and clinicopathological characteristics
of GC. GC samples were classified into low miR-198 ex-
pression group (n = 53) and high miR-198 expression
group (n = 53) according to the median miR-198 expres-
sion level (relative to U6) of all GC samples. The associ-
ation between clinicopathological characteristics and
miR-198 expression was summarized in Table 1. We
found that miR-198 level was associated with tumor size
(p = 0.009), tumor depth (p = 0.005), lymph node metas-
tasis (p = 0.03), and clinical stage (p = 0.02). However, we
did not find any significant correlation between miR-198
levels and other clinicopathological features, such as pa-
tient’s gender, age, Lauren type, and cancer differentiation.
Prognostic values of miR-198 expression in GC patients
We further evaluated the association of miR-198 expres-
sion level with survival of GC patients. Survival analysis
indicated that patients in the high miR-198 expressionFig. 1 miR-198 expression was significantly lower in gastric cancer
samples than in the corresponding noncancerous tissues (p < 0.01,
paired t test). miR-198 expression levels were calculated by the
2−ΔCT method and normalized to U6 small nuclear RNAgroup had better 5-year overall survival than those in
the low miR-198 expression group (p < 0.001, Fig. 2).
Univariate analysis revealed that miR-198 expression
(p < 0.001), tumor size (p = 0.006), tumor depth (p =
0.015), lymph node metastasis (p = 0.028), and TNM
stage (p < 0.001) were prognostic factors for patient’s
overall survival (Table 2). Multivariate analysis con-
firmed low miR-198 expression (p = 0.015, RR = 2.52)
as an unfavorable prognostic indicator independent of
other clinicopathological factors, including depth of
infiltration (p = 0.003, HR = 3.17), lymph node status
(p = 0.012, HR = 2.79), and TNM stage (p = 0.008,
HR = 2.95; Table 2).
Discussion
Identifying novel molecules that take part in GC forma-
tion and progression may be helpful for improving the
diagnosis, prevention and treatment of this disease. The
relationship between miRNAs and tumors has currently
become one of the focuses of cancer studies. Abnormal
expression of several miRNAs has been reported in GC.
For example, miR-1271 was downregulated in GC tis-
sues and correlated with tumor size, lymph node metas-
tasis, and tumor stage [25]. High miR-221 expression
and low miR-34a expression are associated with poor
prognosis in GC patients [26, 27]. Circulating miR-18a
in plasma could discriminate GC patients from healthy
controls with a clinically satisfactory degree of sensitivity
and specificity [28]. Functional analysis indicated that
ectopic miR-874 expression suppressed the growth,
migration, invasion, and tumorigenicity of GC cells,
whereas miR-874 knockdown promoted these pheno-
types [29]. miR-223 and miR-20a could promote cis-
platin resistance of GC cells via regulating cell apoptosis
[30, 31]. These findings suggested that miRNAs mightFig. 2 Kaplan-Meier survival curves of 106 gastric cancer patients
based on miR-198 expression status. Patients in the low expression
group had significantly poorer prognosis than those the in high
expression group (p < 0.001, log-rank test)
Table 2 Univariate and multivariate analysis of overall survival in
106 gastric cancer patients
Variables Univariate analysis Multivariate analysis
RR p value RR p value
Age 0.96 0.228 1.47 0.098
Gender 1.43 0.135 0.98 0.275
Differentiation 1.57 0.096 1.56 0.079
Lauren type 1.35 0.144 1.19 0.212
Tumor size 3.11 0.006 1.55 0.084
Invasion depth 2.87 0.015 3.17 0.003
Lymphatic metastasis 2.59 0.028 2.79 0.012
TNM stage 3.97 <0.001 2.95 0.008
miR-198 expression 3.82 <0.001 2.52 0.015
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and have a great potential for clinical application.
In the current study, we found that miR-198 was
downregulated in human GC tissues compared with
noncancerous tissues. We also found that decreased
miR-198 expression was significantly correlated with ag-
gressive clinicopathological features. Moreover, Kaplan-
Meier analysis showed that GC patients with low miR-
198 expression tend to have shorter overall survival. The
multivariate analysis confirmed low miR-198 expression
as an independent predictor of poor survival. To the au-
thor’s knowledge, this is the first study to analyze the ex-
pression and clinical significance of miR-198 in GC.
Previous research has demonstrated the tumor-
suppressive functions of miR-198 in several human
cancers. Decreased miR-198 expression in colorectal
cancer showed a significant association with histo-
logical grade, T stage, lymph node invasion, and AJCC
stage [18]. Overexpression of miR-198 in colorectal
cancer cell lines inhibited cell proliferation, invasion,
and migration by targeting fucosyl transferase 8
in vitro. In vivo, restoration of miR-198 significantly
inhibited xenograft growth and invasion in nude mice.
In pancreatic cancer, reconstitution of miR-198 re-
sulted in reduced tumor growth and metastasis
through direct targeting MSLN, PBX-1, and VCP [20].
Low miR-198 levels in pancreatic cancer tissue sam-
ples predicted shorter overall survival. In addition,
Yang et al. reported that miR-198 inhibited prolifera-
tion and induced apoptosis of A549 lung cancer cells
via targeting FGFR1 [17]. Tan et al. found that miR-
198 inhibited hepatocellular carcinoma cell invasion
and migration by targeting the HGF/c-MET pathway
[19]. Taken together, these research indicated that loss
of miR-198 might contribute to cancer formation and
progression. However, the complex molecular mecha-
nisms underlying low miR-198 expression in human
cancers and its function are still incompletely known.More studies should be applied to clarify the precise
mechanisms by which miR-198 exerts antitumor
activity.Conclusions
In conclusion, our study showed that miR-198 was
downregulated in GC tissues and correlated with ag-
gressive clinicopathological features. Furthermore, low
miR-198 expression was an important indicator for
unfavorable prognosis of GC patients. Due to the
limited sample size in our study, further prospective
analysis with a large number of tumor samples is
worth doing to verify these conclusions.
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